RxDoctor Payments Data

Verda Hicks, MD

Gynecologic Oncology · Kansas City, MONPI 1407857881

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $671 of the $1,008 with a category attached, or 66.5%. 10 manufacturers reported payments, led by Intuitive Surgical at 50.1% of the total. Reporting peaked in 2019 at $757 and has fallen 75.2% since, to $188 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in MO, where the typical reported total is $1,520.

$1,008in general payments, 2019–2025

Across 28 payments — averaging $36.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$505
  • GSK$150
  • Gen-probe, Inc.$107
  • Merck$92
  • Tesaro, Inc.$62
  • Bayer$22
  • plus $70 from 4 others
$10,112in research payments, 2019–2025

Across 2 payments — averaging $5056.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Fujirebio Diagnostics, Incorporated$10K

What the payments were for

  • Travel & lodging$33833%
  • Food & beverage$67167%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,008 in reported general payments places this provider in the 35th percentile of 38 gynecologic oncology providers in Missouri.

See all gynecologic oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$17,514
Medicare patients
76
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →